CA-YOU.COM
6.3.2024 02:17:34 CET | Business Wire | Press release
You.com announces its designation as one of the few new default browser options on iOS 17.4 for European Union users, alongside significant updates to its AI-powered mobile browsing app, You.com AI Search and Browse.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305667601/en/
Newly Revamped You.com AI Search and Browse App Now Available on iOS 17.4 in the European Union as Part of New Browser Choice Screen (Graphic: Business Wire)
The inclusion in the iOS browser choice screen today highlights You.com's increasing global popularity and dedication to delivering a cutting-edge AI-powered web search and browsing experience loved by its users.
“We're excited to share the latest update to our You.com AI Search and Browse app, now available as a default browser choice on iOS 17.4 for users throughout the European Union. As the only AI chat-native browser option on the new EU browser choice screen for iOS, You.com is setting a new standard for what a browser can do thanks to AI,” said Richard Socher, CEO of You.com.
Socher continued: “With the introduction of 'Ask AI' and a fresh, intuitive app design, we're not just updating features, we're enhancing how you find information online. You.com is more than another way to search and browse — it's an AI Assistant designed to make you more productive, creative, and extraordinary. We invite you to make You.com your default browser for a smarter way to find answers.”
What’s new:
- Introducing “Ask AI”: Dive into the future of search with our new "Ask AI" feature, delivering AI-powered answers complete with citations for a more informative and trustworthy browsing experience.
- A fresh, updated experience: Enjoy a cleaner, more intuitive interface with our updated app design, making navigation smoother and more enjoyable than ever before.
- Enhanced mobile homepage: Discover what's trending with an improved mobile home page that now offers trending suggestions, keeping you informed and engaged with the latest and most relevant content.
With You.com, users can say goodbye to endless scrolling through blue links and tedious websites. Search alone is inefficient for in-depth research, and ineffective at answering complex, multi-step questions. A conversational search experience powered by cutting-edge AI, You.com delivers immediate, comprehensive answers across any topic, supplemented by follow-up suggestions for deeper exploration.
You.com enhances the efficiency of finding information and enriches the quality of results with advanced AI functionalities that support text generation, content summarization, image creation, and more. You.com stands out for its powerful AI Modes, from its Research Mode which can browse and synthesize information from multiple websites simultaneously with extensive citations to its Genius Mode capable of multi-step complex problem solving.
Whether users prefer traditional search methods or the enriched, AI-enhanced search, You.com offers seamless management of searches, chats, and visited websites, with easy options for saving or deleting history. Linked citations further empower users to verify responses and delve into sources, ensuring a trustworthy and comprehensive browsing experience.
You.com also prioritizes privacy, offering ad-blocking, pop-up blocking, and tracking protection capabilities.
Download You.com today for free and experience a better way to search.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305667601/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom